lonafarnib has been researched along with bortezomib in 2 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (bortezomib) | Trials (bortezomib) | Recent Studies (post-2010) (bortezomib) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 6,868 | 860 | 4,753 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
| Chen, J; David, E; Khuri, FR; Lonial, S; Sun, SY; Waller, EK | 1 |
1 review(s) available for lonafarnib and bortezomib
| Article | Year |
|---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |
1 other study(ies) available for lonafarnib and bortezomib
| Article | Year |
|---|---|
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
Topics: Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Phosphorylation; Piperidines; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured | 2005 |